ALPHARETTA, Ga., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its fourth quarter and full year 2023 financial results will be reported on Tuesday, March 12, 2024 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corpora ...

ALPHARETTA, Ga., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. ("Clearside" or the "Company") (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that it has entered into a securities purchase agreement with institutional investors and an existing stockholder, providing for the purchase and sale of 11,111,111 shares of common stock and accompanying warrant to purchase up to 11,111, ...

Clearside Biomedical, Inc. (NASDAQ:CLSD) Q3 2023 Results Conference Call November 13, 2023 4:30 PM ET Company Participants Jenny Kobin - IR George Lasezkay - CEO Charlie Deignan - CFO Conference Call Participants Serge Belanger - Needham & Company Jon Wolleben - JMP Securities Jack Padovano - Stifel Yi Chen - H.C. Wainwright Operator Greetings, and welcome to the Clearside Biomedical Third Quarter 2023 Financial Results and Corporate Update Call. At this time, all participants are in a listen-only mode and ...

Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of income and expenses during the reporting periods. Significant items subject to such estimates and assumptions include revenue recognition, the accounting for useful lives to calculate ...

Clearside Biomedical, Inc. (NASDAQ:CLSD) Q2 2023 Results Conference Call August 14, 2023 4:30 PM ET Company Participants Jenny Kobin - IR George Lasezkay - CEO Charlie Deignan - CFO Conference Call Participants Jon Wolleben - JMP Securities Shawn Kim - Jones Trading Rohit Bhasin - Needham & Company Jack Padavano - Stifel Yi Chen - H.C. Wainwright Operator Greetings, and welcome to the Clearside Biomedical Second Quarter 2023 Financial Results and Corporate Update Call. [Operator Instructions] Please note, t ...

FORM 10-Q | --- | --- | |------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------| | Clearside Biomedical, \n(Exact Name of Registrant as \nDelaware | Inc. \nSpecified in its Charter) \n45-2437375 | | (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | | 900 North Point Parkway, Suite 200 Alpharetta, GA (Address of principal executive offices) | ...

Clearside Biomedical, Inc. (NASDAQ:CLSD) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET Company Participants Jenny Kobin - Investor Relations George Lasezkay - President and Chief Executive Officer Charles Deignan - Chief Financial Officer Conference Call Participants Serge Belanger - Needham & Company Annabel Samimy - Stifel Andreas Argyrides - Wedbush Securities Yi Chen - H.C. Wainwright Operator Good day and thank you for standing by. Welcome to the Clearside Biomedical First Quarter 2023 Finan ...

Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share CLSD The Nasdaq Stock Market LLC Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐ In ...

Novel SCS Microinjector® shows a demonstrated ability for precise delivery into the suprachoroidal space SCS injection procedure commercially accepted by retinal physicians following launch of XIPERE® • Thousands of SCS injections performed Safety profile comparable to intravitreal injections1 • No Serious Adverse Events (SAEs) involving lens injury, suprachoroidal hemorrhage, or endophthalmitis have been observed 6 clinical trials ongoing including partner programs Sources: Clearside data on file | 1Kurup, ...

DOCUMENTS INCORPORATED BY REFERENCE Portions of the Company's definitive proxy statement, to be filed pursuant to Regulation 14A under the Securities Exchange Act of 1934, for its 2023 Annual Meeting of Stockholders are incorporated by reference in Part III of the Form 10-K. The risk factors summarized below could materially harm our business, operating results, and/or financial condition, impair our future prospects and/or cause the price of our common stock to decline. These risks are discussed more fully ...